文献速递前列腺癌

基于18F-DCFPyL PSMA-PET/CT的列线图预测前列腺癌侧别特异性包膜外侵犯

Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT-based nomogram.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-07-23

多变量分析确定PSA、MRI检测的EPE、GGG、肿瘤受累百分比和SUVmax≥13为显著预测因子。整合PSMA PET与MRI的列线图优于仅MRI模型(中位AUC 0.7542 vs. 0.7350,p<0.001),校准良好且临床净获益更高。

要点

  • PSMA PET的SUVmax≥13是侧别特异性EPE的显著预测因子。
  • 整合PSMA PET、MRI和临床病理变量的列线图预测EPE优于仅MRI模型。
  • 该列线图可辅助术前评估,有助于改善术后功能结局。

核心结论

  • 整合PSMA PET与MRI及临床病理变量的列线图能预测侧别特异性EPE,且优于本机构仅MRI模型。
  • PSMA摄取强烈预测侧别特异性EPE,可增强术前评估并改善术后功能结局。

研究设计与样本

  • 基线变量包括人口学、PSA、活检、MRI和PSMA参数(SUVmax、EPE、SVI)。
  • 主要终点为最终病理的侧别特异性EPE;采用单变量和多变量逻辑回归筛选预测因子并构建列线图。
  • 使用1000次迭代bootstrap方法比较三种模型:机构2018年仅MRI模型、MRI+PSMA固定模型、基于每个bootstrap样本重新训练的MRI+PSMA模型。

主要发现

  • MRI检测EPE为18.9%,PSMA PET检测EPE为5.4%;腺体内SUVmax中位数为11.30。
  • EPE阳性侧别更常见MRI/PSMA检测的EPE(p<0.001)、PIRADS 5病变(p<0.001)、侵袭性活检GGG(p<0.001)、更高阳性针数(p<0.001)和更大肿瘤受累百分比(p<0.001)。
  • EPE组中位SUVmax显著更高(9.1 vs. 5.4;p<0.001)。
  • 多变量分析确定PSA、MRI检测的EPE、GGG、肿瘤受累百分比和SUVmax≥13为显著预测因子。
  • PSMA+MRI固定模型优于仅MRI模型(中位AUC:0.7542 vs. 0.7350),p<0.001;校准图显示预测概率与观察概率高度一致,决策曲线分析显示在相关阈值范围内净临床获益更大。

关键数值与推荐

  • PSMA+MRI固定模型的中位AUC为0.7542,仅MRI模型为0.7350,比较p<0.001。
  • EPE组中位SUVmax为9.1,非EPE组为5.4,p<0.001。
  • 多变量分析中SUVmax≥13为显著预测因子。
  • MRI检测EPE率为18.9%,PSMA PET检测EPE率为5.4%;腺体内SUVmax中位数为11.30。

临床怎么用

  • 可利用整合PSMA PET、MRI和临床病理变量的列线图术前预测侧别特异性EPE。
  • PSMA摄取(SUVmax≥13)可作为侧别特异性EPE的预测指标,辅助制定神经保留策略。
  • 该模型可能改善术前评估并有助于优化术后功能结局。

局限性

  • 单中心、单一术者队列,外部推广性需进一步验证。
  • 回顾性设计可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extraprostatic extension (EPE) in prostate cancer (PCa) has implications for nerve-sparing approaches. mpMRI-based nomograms show modest accuracy, highlighting the need for improved predictive models. This study evaluates 18F-DCFPyL prostate-specific membrane antigen (PSMA) positron emission tomography/ computed tomography (PET/CT) for predicting side-specific EPE using maximum standardized uptake value (SUVmax). METHODS: This single-center cohort study included patients undergoing RALP by a single surgeon (AKT) from January 2022 to September 2024. Baseline variables included demographics, PSA, biopsy, MRI, and PSMA parameters (SUVmax, EPE, SVI). The primary endpoint was side-specific EPE on final pathology. Univariable and multivariable logistic regression identified significant predictors. A nomogram was built based on this. To evaluate model performance, a 1000-iteration bootstrap approach was used to compare (1) the institutional MRI-only 2018 model, (2) an MRI + PSMA Fixed Model, and (3) a retrained MRI + PSMA Model built on each bootstrap sample. RESULTS: Three hundred fifty-five patients were analyzed. EPE was detected in 18.9% by MRI and 5.4% by PSMA PET. Median intraprostatic SUVmax was 11.30. EPE-positive sides were more likely to have MRI/PSMA-detected EPE (p < 0.001), PIRADS 5 lesions (p < 0.001), aggressive biopsy GGG (p < 0.001), higher positive cores (p < 0.001), and greater percent tumor involvement (p < 0.001). Median SUVmax was significantly higher in the EPE group (9.1 vs. 5.4; p < 0.001). Multivariable analysis identified PSA, MRI-detected EPE, GGG, tumor involvement percentage, and SUVmax ≥13 as significant predictors. The PSMA + MRI Fixed Model outperformed the MRI-only model (median AUC: 0.7542 vs. 0.7350) with p < 0.001. Calibration plots showed strong agreement between predicted and observed probabilities, and decision curve analysis demonstrated greater net clinical benefit across relevant thresholds. CONCLUSION: We developed a nomogram integrating PSMA PET with MRI and clinicopathological variables, outperforming our institutional model. PSMA uptake strongly predicts side-specific EPE, which can enhance preoperative assessment and improve postoperative functional outcomes.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tillu N, Maheshwari A, Kolanukuduru K, et al. Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT-based nomogram. Prostate Cancer Prostatic Dis. 2025. PMID: 40702303. doi:10.1038/s41391-025-01001-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。